MedTrace Logo

Evaluate the Efficacy of Oxybutynin Chloride in Patients With Primary Hyperhidrosis

NCT02099695 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2016-07-26

No results posted yet for this study

Summary

Treatment of primary hyperhidrosis through a comparative study between oxybutynin hydrochloride and placebo.

Hydrochloride may decrease the symptoms of hyperhidrosis improving the subject's quality of life.

Conditions

  • Hyperhidrosis

Interventions

DRUG

Oxybutynin

The doses will increase due to the absence/ lack of therapeutic response of the previous dose assessed during the study visits.

DRUG

Placebo

The quantity of tablets will increase due to the absence/ lack of therapeutic response.

Sponsors & Collaborators

  • Hospital Israelita Albert Einstein

    collaborator OTHER

  • University of Sao Paulo

    collaborator OTHER

  • Cristália Produtos Químicos Farmacêuticos Ltda.

    lead INDUSTRY

Principal Investigators

  • José R Milanez de Campos · Hospital Israelita Albert Einstein

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2016-01-31
Completion
2016-02-29

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02099695 on ClinicalTrials.gov